Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High DOCK1 expression identifies a distinct prognostic subgroup of pediatric acute myeloid leukemia: Results of the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 trial.
Yoshitomi M, Tsujimoto SI, Ikeda J, Kawai T, Ohki K, Hara Y, Yamato G, Tanoshima R, Tomizawa D, Shimada A, Horibe K, Adachi S, Taga T, Tawa A, Hayashi Y, Ito S, Shiba N. Yoshitomi M, et al. Among authors: tawa a. Pediatr Blood Cancer. 2024 Sep;71(9):e31151. doi: 10.1002/pbc.31151. Epub 2024 Jul 2. Pediatr Blood Cancer. 2024. PMID: 38953149
Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in Japan.
Taga T, Watanabe T, Tomizawa D, Kudo K, Terui K, Moritake H, Kinoshita A, Iwamoto S, Nakayama H, Takahashi H, Shimada A, Taki T, Toki T, Ito E, Goto H, Koh K, Saito AM, Horibe K, Nakahata T, Tawa A, Adachi S. Taga T, et al. Among authors: tawa a. Pediatr Blood Cancer. 2016 Feb;63(2):248-54. doi: 10.1002/pbc.25789. Epub 2015 Oct 20. Pediatr Blood Cancer. 2016. PMID: 26481183 Clinical Trial.
High PRDM16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to FLT3-ITD, KMT2A-PTD, and NUP98-NSD1: the results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 trial.
Shiba N, Ohki K, Kobayashi T, Hara Y, Yamato G, Tanoshima R, Ichikawa H, Tomizawa D, Park MJ, Shimada A, Sotomatsu M, Arakawa H, Horibe K, Adachi S, Taga T, Tawa A, Hayashi Y. Shiba N, et al. Among authors: tawa a. Br J Haematol. 2016 Feb;172(4):581-91. doi: 10.1111/bjh.13869. Epub 2015 Dec 18. Br J Haematol. 2016. PMID: 26684393 Free article.
CXCR4 Overexpression is a Poor Prognostic Factor in Pediatric Acute Myeloid Leukemia With Low Risk: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group.
Matsuo H, Nakamura N, Tomizawa D, Saito AM, Kiyokawa N, Horibe K, Nishinaka-Arai Y, Tokumasu M, Itoh H, Kamikubo Y, Nakayama H, Kinoshita A, Taga T, Tawa A, Taki T, Tanaka S, Adachi S. Matsuo H, et al. Among authors: tawa a. Pediatr Blood Cancer. 2016 Aug;63(8):1394-9. doi: 10.1002/pbc.26035. Epub 2016 May 2. Pediatr Blood Cancer. 2016. PMID: 27135782
Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia.
Shiba N, Yoshida K, Hara Y, Yamato G, Shiraishi Y, Matsuo H, Okuno Y, Chiba K, Tanaka H, Kaburagi T, Takeuchi M, Ohki K, Sanada M, Okubo J, Tomizawa D, Taki T, Shimada A, Sotomatsu M, Horibe K, Taga T, Adachi S, Tawa A, Miyano S, Ogawa S, Hayashi Y. Shiba N, et al. Among authors: tawa a. Blood Adv. 2019 Oct 22;3(20):3157-3169. doi: 10.1182/bloodadvances.2019000404. Blood Adv. 2019. PMID: 31648321 Free PMC article.
Attempts to optimize postinduction treatment in childhood acute myeloid leukemia without core-binding factors: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG).
Hasegawa D, Tawa A, Tomizawa D, Watanabe T, Saito AM, Kudo K, Taga T, Iwamoto S, Shimada A, Terui K, Moritake H, Kinoshita A, Takahashi H, Nakayama H, Koh K, Goto H, Kosaka Y, Miyachi H, Horibe K, Nakahata T, Adachi S. Hasegawa D, et al. Among authors: tawa a. Pediatr Blood Cancer. 2020 Dec;67(12):e28692. doi: 10.1002/pbc.28692. Epub 2020 Sep 4. Pediatr Blood Cancer. 2020. PMID: 32886449
High IL2RA/CD25 expression is a prognostic stem cell biomarker for pediatric acute myeloid leukemia without a core-binding factor.
Aoki T, Shiba N, Tsujimoto S, Yamato G, Hara Y, Kato S, Yoshida K, Ogawa S, Hayashi Y, Iwamoto S, Taki T, Shimada A, Iijima-Yamashita Y, Horibe K, Tawa A, Taga T, Adachi S, Tomizawa D. Aoki T, et al. Among authors: tawa a. Pediatr Blood Cancer. 2024 Feb;71(2):e30803. doi: 10.1002/pbc.30803. Epub 2023 Dec 6. Pediatr Blood Cancer. 2024. PMID: 38054691
KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group.
Shimada A, Taki T, Tabuchi K, Tawa A, Horibe K, Tsuchida M, Hanada R, Tsukimoto I, Hayashi Y. Shimada A, et al. Among authors: tawa a. Blood. 2006 Mar 1;107(5):1806-9. doi: 10.1182/blood-2005-08-3408. Epub 2005 Nov 15. Blood. 2006. PMID: 16291592 Free article.
Prognostic significance of the BAALC isoform pattern and CEBPA mutations in pediatric acute myeloid leukemia with normal karyotype: a study by the Japanese Childhood AML Cooperative Study Group.
Mizushima Y, Taki T, Shimada A, Yui Y, Hiraumi Y, Matsubara H, Watanabe M, Watanabe K, Kamitsuji Y, Hayashi Y, Tsukimoto I, Kobayashi R, Horibe K, Tawa A, Nakahata T, Adachi S. Mizushima Y, et al. Among authors: tawa a. Int J Hematol. 2010 Jun;91(5):831-7. doi: 10.1007/s12185-010-0585-x. Epub 2010 May 22. Int J Hematol. 2010. PMID: 20495894
128 results